| Literature DB >> 32589162 |
Takenori Inomata1,2,3, Masahiro Nakamura4, Masao Iwagami5, Akie Midorikawa-Inomata3, Jaemyoung Sung1,6, Keiichi Fujimoto7, Yuichi Okumura2,7, Atsuko Eguchi3, Nanami Iwata7, Maria Miura7, Kenta Fujio7, Ken Nagino3, Satoshi Hori8, Kazuo Tsubota9, Reza Dana10, Akira Murakami1.
Abstract
BACKGROUND: Discontinuation of contact lens use is mainly caused by contact lens-associated dry eye. It is crucial to delineate contact lens-associated dry eye's multifaceted nature to tailor treatment to each patient's individual needs for future personalized medicine.Entities:
Keywords: DryEyeRhythm; ResearchKit; contact lens-associated dry eye; dry eye; mobile health; mobile phone; risk factors; smartphone app; stratification; subjective symptoms
Year: 2020 PMID: 32589162 PMCID: PMC7381048 DOI: 10.2196/18996
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Trends in the number of downloads.
Figure 2Flow chart of the enrollment process used in this study. CL: contact lens.
Subjective symptoms of contact lens–associated dry eye.
| Daily subjective symptoms | Non-CLADEa (n=397) | CLADE (n=1447) | ||||||
| Eye itching (0-10), median (IQR) | 0 (0-2) | 2 (0-5) | <.001 | |||||
| Asthenopia (yes), n (%) | 147 (37.0) | 899 (62.1) | <.001 | |||||
| Headache (0-10), median (IQR) | 0 (0-2) | 1 (0-4) | <.001 | |||||
| Mental fatigue (yes), n (%) | 57 (14.4) | 446 (30.8) | <.001 | |||||
| Stiffness and pain of body axis muscle (yes), n (%) | 151 (38.0) | 816 (56.4) | <.001 | |||||
| Stress (1-10), median (IQR) | 4 (2-6) | 5 (3-7) | <.001 | |||||
| J-OSDIb total score (1-100), median (IQR) | 8.3 (6.3-10.4) | 30 (20.8-43.8) | <.001 | |||||
|
| 15 (5-20) | 35 (25-45) | <.001 | |||||
|
| (1) Eyes that are sensitive to light (0-4), median (IQR) | 1 (0-1) | 1 (1-3) | <.001 | ||||
|
| (2) Eyes that feel gritty (0-4), median (IQR) | 1 (0-1) | 1 (1-2) | <.001 | ||||
|
| (3)Painful or sore eyes (0-4), median (IQR) | 0 (0-1) | 1 (1-2) | <.001 | ||||
|
| (4) Blurred vision (0-4), median (IQR) | 0 (0-1) | 1 (1-2) | <.001 | ||||
|
| (5) Poor vision (0-4), median (IQR) | 0 (0-1) | 1 (1-2) | <.001 | ||||
|
| 0 (0) | 12.5 (6.3-25) | <.001 | |||||
|
| (6) Reading (0-4), median (IQR) | 0 (0) | 1 (0-1) | <.001 | ||||
|
| (7) Driving at night (0-4), median (IQR) | 0 (0) | 0 (0-1) | <.001 | ||||
|
| (8) Working with a computer or bank machine (0-4), median (IQR) | 0 (0) | 0 (0-1) | <.001 | ||||
|
| (9) Watching TV (0-4), median (IQR) | 0 (0) | 1 (0-1) | <.001 | ||||
|
| 8.3 (8.3-16.7) | 41.7 (25-66.7) | <.001 | |||||
|
| (10) Windy conditions (0-4), median (IQR) | 0 (0) | 1 (1-3) | <.001 | ||||
|
| (11) Places or areas with low humidity (0-4), | 0 (0-1) | 2 (1-3) | <.001 | ||||
|
| (12) Areas that are air conditioned (0-4), median (IQR) | 0 (0-1) | 2 (1-3) | <.001 | ||||
| SDSc score (20-80), median (IQR) | 42 (36-49) | 48 (41-55) | <.001 | |||||
| SDS score >40, n (%) | 234 (58.9) | 1159 (80.1) | <.001 | |||||
aCLADE: contact lens–associated dry eye.
bJ-OSDI: Japanese Ocular Surface Disease Index.
cSDS: Zung Self-Rating Depression Scale.
Figure 3Stratification of subjective symptoms of CLADE. (A) The number of subjective symptoms in the non-CLADE and CLADE groups. (B) The frequency of subjective symptoms of DED based on each OSDI questionnaire. (C) The treemap shows the difference in the frequency of subjective symptoms of DED (the percentage of subjective symptoms in the CLADE group minus the percentage of subjective symptoms in the non-CLADE group) based on each OSDI question. (D) The Pearson correlation coefficients between subjective symptoms and CLADE are shown in the heatmap as a color gradient. (E) t-SNE projection shows the groups of CLADE based on the subjective symptoms. (F) The heatmap shows the correlation between the groups made by t-SNE projection and each OSDI item. CLADE: contact lens–associated dry eye. DED: dry eye disease. OSDI: Ocular Surface Disease Index. t-SNE: t-distributed Stochastic Neighbor Embedding.
Univariate and multivariate adjusted odds ratios of risk factors for contact lens–associated dry eye.
| Risk factors | Univariate | Multivariate | |||||||
|
| |||||||||
|
| Age (per year) | 0.99 (0.975-0.998) | 0.98 (0.96-0.99) | ||||||
|
| Sex (female vs male) | 1.75 (1.33-2.23) | 1.53 (1.05-2.24) | ||||||
|
| Height (cm) | 0.98 (0.97-0.99) | 1.00 (0.98-1.02) | ||||||
|
| Weight (kg) | 0.99 (0.98-1.00) | N/Aa | ||||||
| CLb use (0-10 years) | 0.98 (0.95-1.02) | 0.99 (0.95-1.03) | |||||||
|
|
|
| |||||||
|
| 0-6 | 1 (N/A) | 1 (N/A) | ||||||
|
| 7-12 | 1.25 (0.77-2.05) | 1.28 (0.76-2.14) | ||||||
|
| 13-18 | 1.19 (0.74-1.92) | 1.24 (0.74-2.06) | ||||||
|
| 19-24 | 1.77 (0.93-3.36) | 1.45 (0.73-2.85) | ||||||
|
|
|
| |||||||
|
| Hard | 1 (N/A) | 1 (N/A) | ||||||
|
| Disposable (daily) | 0.98 (0.61-1.58) | 0.82 (0.49-1.36) | ||||||
|
| Disposable (biweeklyc) | 0.87 (0.54-1.40) | 0.76 (0.46-1.28) | ||||||
|
| Disposable (monthly) | 1.30 (0.71-2.39) | 0.92 (0.48-1.77) | ||||||
|
| Conventional lens | 1.23 (0.63-2.39) | 0.90 (0.44-1.83) | ||||||
| Medicated hypertension (yes vs no) | 0.51 (0.23-1.16) | N/A | |||||||
| Diabetes (yes vs no) | 0.96 (0.20-4.64) | N/A | |||||||
|
|
|
| |||||||
|
| Blood disease | 1.92 (0.24-15.69) | N/A | ||||||
|
| Brain disease | 0.68 (0.13-3.54) | N/A | ||||||
|
| Collagen disease | 2.20 (0.27-17.65) | N/A | ||||||
|
| Heart disease | 2.12 (0.63-7.10) | N/A | ||||||
|
| Kidney disease | 2.91 (0.68-12.50) | N/A | ||||||
|
| Liver disease | 1.51 (0.33-6.85) | N/A | ||||||
|
| Malignant tumor | N/A | N/A | ||||||
|
| Respiratory disease | 1.62 (0.96-2.75) | N/A | ||||||
| Hay fever (yes vs no) | 1.41 (1.13-1.77) | 1.38 (1.10-1.74) | |||||||
|
|
|
| |||||||
|
| Depression | 1.91 (0.86-4.26) | N/A | ||||||
|
| Schizophrenia | 1.01 (0.28-3.62) | N/A | ||||||
|
| Other | 3.13 (1.43-6.84) | 2.51 (1.13-5.57) | ||||||
| Past diagnosis of dry eye disease | 2.11 (1.58-2.82) | 2.21 (1.63-2.99) | |||||||
|
|
|
| |||||||
|
| Cataract surgery | N/A | N/A | ||||||
|
| LASIKd | 0.27 (0.04-1.95) | N/A | ||||||
|
| Other | 2.58 (0.91-7.28) | N/A | ||||||
| Coffee (per cup per day) | 1.00 (0.92-1.10) | N/A | |||||||
|
|
|
| |||||||
|
| <4 | 1 (N/A) | 1 (N/A) | ||||||
|
| 4-8 | 1.08 (0.80-1.45) | 1.07 (0.79-1.45) | ||||||
|
| >8 | 1.56 (1.11-2.19) | 1.61 (1.13-2.28) | ||||||
| Periodic exercise (yes vs no) | 0.83 (0.66-1.05) | N/A | |||||||
|
|
|
| |||||||
|
| <6 | 1.05 (0.82-1.36) | N/A | ||||||
|
| 6-9 | 1 (N/A) | N/A | ||||||
|
| >9 | 1.24 (0.91-1.68) | N/A | ||||||
| Smoking (yes vs no) | 1.69 (1.26-2.28) | 2.07 (1.49-2.88) | |||||||
| Water intake (per 100 mL/d) | 1.00 (1.00-1.00) | N/A | |||||||
aN/A: not applicable.
bCL: contact lens.
cBiweekly: every 2 weeks.
dLASIK: laser-assisted in situ keratomileusis.